Article Text

Download PDFPDF

Treatment of latent tuberculosis with rifampicin is associated with higher completion rates
  1. V Nadig
  1. Clinical Fellow, Papworth Hospital, Cambridge, UK; vidya.nadig{at}

Statistics from

In this retrospective study, medical records of 2255 patients who received treatment for latent tuberculosis infection (LTBI) at a US centre between January 1999 and January 2004 were reviewed. Adherence to LTBI treatment was compared between two groups of patients. One group (843 patients) received isoniazid for 9 months and the other (1412 patients) received rifampicin for 4 months.

In the isoniazid group 52.6% of patients completed 80% or more of the LTBI treatment, compared with 71.6% of the rifampicin group (p<0.001). However, similar percentages of people completed 4 months’ of treatment in both groups. Adverse reactions leading to discontinuation of treatment by the clinician were higher in the isoniazid group (4.6%) compared with the rifampicin group (1.9%, p<0.001) and this result was not explained by greater duration of exposure to isoniazid.

This study shows significantly higher adherence to LTBI treatment with a 4 month regime of rifampicin compared with 9 months of isoniazid. Further studies are warranted to look at the efficacy of rifampicin in the treatment of LTBI.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.